Cyclerion Therapeutics

Focus: Cyclerion Therapeutics is a Cambridge-based private biotech focused on soluble guanylate cyclase (sGC) activators for metabolic, rare, and cardiovascular diseases. The company operates at the pre-revenue stage with an early-stage pipeline spanning Phase 1 and Phase 2 programs.

Metabolic Diseases Rare Diseases Cardiovascular

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Open Jobs

About Cyclerion Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Cyclerion Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Olinciguat

Healthy

Phase 1

Clinical Trials (1)

NCT03892499A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers

Phase 1

Help build intelligence for Cyclerion Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to an emerging drug class (sGC activators) with applications across high-unmet-need indications including sickle cell disease, heart failure with preserved ejection fraction, and type 2 diabetes with nephropathy
Multiple Phase 2 programs (4 active Phase 2 trials) provide near-term clinical catalysts and decision points
Founded on a focused therapeutic platform with potential for competitive differentiation in cardiovascular and metabolic disease

Watch Out For

Zero current job openings signals no active hiring; company may be in restructuring, pause, or pre-exit mode
Early-stage pipeline (7 Phase 1, 4 Phase 2, 0 Phase 3) means no near-term commercial upside or revenue inflection
Private status with undisclosed funding creates visibility gaps on runway, financial stability, and exit timeline

Generated by Claude from Cyclerion Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IW-1973

Healthy

Phase 1

Clinical Trials (1)

NCT03499106A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers

Phase 1

IW-1973

Healthy

Phase 1

Clinical Trials (1)

NCT02616861Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Phase 1

IW-1701

Healthy

Phase 1

Clinical Trials (1)

NCT02792998A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects